Company
Headquarters: Stockholm, Sweden
Employees: 2
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Modus Therapeutics Holding Ab, a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It is developing Sevuparin, a polysaccharide to treat patients with sepsis and septic shock. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB has the following listings and related stock indices.
Stock: OMX: MODTX